| pubmed-article:2092283 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C1556085 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0024501 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0032952 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0521116 | lld:lifeskim |
| pubmed-article:2092283 | lifeskim:mentions | umls-concept:C0085752 | lld:lifeskim |
| pubmed-article:2092283 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2092283 | pubmed:dateCreated | 1991-6-13 | lld:pubmed |
| pubmed-article:2092283 | pubmed:abstractText | 277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients. | lld:pubmed |
| pubmed-article:2092283 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2092283 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2092283 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2092283 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:2092283 | pubmed:issn | 0378-584X | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:BartelsHH | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:LeeHH | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:DeicherHH | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:FischerJ TJT | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:BartlRR | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:GramatzkiMM | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:PeestDD | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:BraunH JHJ | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:ColdeweyRR | lld:pubmed |
| pubmed-article:2092283 | pubmed:author | pubmed-author:von BroenI... | lld:pubmed |
| pubmed-article:2092283 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2092283 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:2092283 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2092283 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2092283 | pubmed:pagination | 458-60 | lld:pubmed |
| pubmed-article:2092283 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:meshHeading | pubmed-meshheading:2092283-... | lld:pubmed |
| pubmed-article:2092283 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2092283 | pubmed:articleTitle | Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Treatment Group. | lld:pubmed |
| pubmed-article:2092283 | pubmed:affiliation | Abt. Immunologie und Transfusionsmedizin, Zentrum Innere Medizin und Dermatologie Med. Hochschule Hannover, FRG. | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:2092283 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2092283 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2092283 | lld:pubmed |
